首页> 外文OA文献 >Serum antioxidants as predictors of the adult respiratory distress syndrome in septic patients
【2h】

Serum antioxidants as predictors of the adult respiratory distress syndrome in septic patients

机译:血清抗氧化剂作为脓毒症患者成人呼吸窘迫综合征的预测因子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adult respiratory distress syndrome (ARDS) can develop as a complication of various disorders, including sepsis, but it has not been possible to identify which of the patients at risk will develop this serious disorder. We have investigated the ability of six markers, measured sequentially in blood, to predict development of ARDS in 26 patients with sepsis.At the initial diagnosis of sepsis (6-24 h before the development of ARDS), serum manganese superoxide dismutase concentration and catalase activity were higher in the 6 patients who subsequently developed ARDS than in 20 patients who did not develop ARDS. These changes in antioxidant enzymes predicted the development of ARDS in septic patients with the same sensitivity, specificity, and efficiency as simultaneous assessments of serum lactate dehydrogenase activity and factor VIII concentration. By contrast, serum glutathione peroxidase activity and α1Pi-elastase complex concentration did not differ at the initial diagnosis of sepsis between patients who did and did not subsequently develop ARDS, and were not as effective in predicting the development of ARDS.Measurement of manganese superoxide dismutase and catalase, in addition to the other markers, should facilitate identification of patients at highest risk of ARDS and allow prospective treatment.
机译:成人呼吸窘迫综合征(ARDS)可以发展为包括败血症在内的各种疾病的并发症,但尚无法确定哪些高危患者会发展为这种严重疾病。我们调查了在血液中顺序测量的六个标记物预测26例败血症患者ARDS的能力的能力。在脓毒症的初步诊断(ARDS发生前6-24小时),血清锰超氧化物歧化酶浓度和过氧化氢酶随后发生ARDS的6例患者的活性高于未发生ARDS的20例患者。这些抗氧化酶的变化预示着败血症患者ARDS的发展,其敏感性,特异性和效率与同时评估血清乳酸脱氢酶活性和VIII因子浓度相同。相比之下,在初次确诊为败血症的患者之间,血清谷胱甘肽过氧化物酶活性和α1Pi-弹性蛋白酶复合物浓度在初诊时并没有差异,并且在预测ARDS的发展方面没有那么有效。锰超氧化物歧化酶的测定除其他标记外,过氧化氢酶和过氧化氢酶还应有助于识别ARDS风险最高的患者,并允许进行前瞻性治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号